Skip to main content

Table 1 Patients’ characteristics and clinical features

From: VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma

Patient

Tumor location

N surgeries pre-bev

n bev cycles

Best response

Toxicity (grade)

PFS (mos)

OS (mos)

1

R temporal

3

11

CR

none

51

71

2

R parietal

1

12

CR

none

36

41

3

R temporal

1

1

PD

brain hemorrhage

3

4

4

R parietal

2

2

SD

hepatic failure

6

8

5

L temporal

1

9

CR

none

40

48

6

multifocal

1

2

PD

brain hemorrhage

6

7

7

L occipital

1

NA

NA

NA

NA

NA

8

multifocal

1

NA

NA

NA

NA

NA

9

L parietal

2

NA

NA

NA

NA

NA

10

R parietal

1

NA

NA

NA

NA

NA

11

R temporal

1

NA

NA

NA

NA

NA

12

L parietal

1

NA

NA

NA

NA

NA